Bayer Sells Contraceptive Business to Apollo for €3 Billion

Bayer has completed the sale of its contraceptive manufacturing division to Apollo for €3 billion. The transaction is viewed as a significant financial move for the German pharmaceutical giant. The sale aims to strengthen Bayer’s balance sheet. The €3 billion cash inflow will be used to reduce debt and improve liquidity. The transaction also seeks to ease the financial pressure stemming from long‑standing lawsuits over the Roundup herbicide. Legal proceedings related to Roundup have negatively impacted Bayer’s cash flow and created challenges in its capital structure. By divesting its contraceptive arm, the company can lessen this burden and refocus its strategic priorities. Market participants see the development as a positive signal, lowering Bayer’s risk profile and boosting investor confidence. The company plans to deploy the proceeds into research and development. This is not investment advice.